NanoBio Corporation
Ann Arbor, Michigan, United States
Purpose
to develop an effective, stable intranasal nanoemulsion adjuvanted respiratory syncytial virus (RSV) vaccine for the developing world without the hyper-reactivity observed with prior RSV vaccines in clinical trials
Division
Global Health
Date
November 2010
Region Served
GLOBAL
Committed amount
$5,930,094
Grant topic
Pneumonia
Duration (months)
35
Grantee location
Ann Arbor, Michigan, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.